within Pharmacolibrary.Drugs.ATC.A;

model A03AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Benzilone is an antimuscarinic (anticholinergic) agent previously used as an antispasmodic to treat gastrointestinal disorders such as peptic ulcers and irritable bowel syndrome. It is no longer widely used today and has largely been replaced by newer agents.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data are available for benzilone in the scientific literature. The following values are rough estimates based on the known properties and pharmacology of structurally similar antimuscarinic agents.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0320-8\">10.1007/s40261-015-0320-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26334726/\">https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1991.tb03673.x\">10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1753010/\">https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=\"https://doi.org/10.1007/s11095-021-03078-w\">10.1007/s11095-021-03078-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34341958/\">https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AB01;
